Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Diana, Morlote"'
Autor:
Saurabh Zanwar, Jithma P. Abeykoon, Surendra Dasari, Aishwarya Ravindran, Jason R. Young, Aldo A. Acosta-Medina, Karen L. Rech, Jonathan Schwartz, Aaron Mangold, Allison Rosenthal, N. Nora Bennani, Mithun V. Shah, Diana Morlote, Gaurav Goyal, Ronald S. Go
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 6, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/4f3228285e1f4e578bd0476fead1756c
Autor:
Sydney Dunn-Valadez, Srilakshmi Bathini, Carly Elston, Sravanti Rangaraju, Antonio Di Stasi, Sarah Worth, Diana Morlote, Shuko Harada, Pankit Vachhani
Publikováno v:
Cancer Treatment and Research Communications, Vol 31, Iss , Pp 100560- (2022)
Ivosidenib is an oral inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). It is approved for treatment of patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) and patients with newly diagnosed IDH1-mutated AML who are 75
Externí odkaz:
https://doaj.org/article/2fa1bcd8c31444e0bc126a135dcd519a
Publikováno v:
Clinics in Laboratory Medicine. 42:385-394
Molecular testing is now considered the standard of care to screen for disease, confirm the diagnosis, guide management, and use target therapy. Currently, several testing strategies are being used. One of the most common strategies is single-gene te
Autor:
Zoran Gatalica, Carlos Prieto-Granada, Elena Florento, Paul Rodriguez-Waitkus, Todd M. Stevens, Diana Morlote, Jeffrey Swensen, Peter G. Pavlidakey, Cristina Ramirez
Publikováno v:
Journal of Cutaneous Pathology. 48:1139-1149
Background Adnexal skin tumors are diagnostically challenging with few known molecular signatures. Recently, however, YAP1-MAML2 and YAP1-NUTM1 fusions were identified in poroid adnexal skin tumors. Methods Herein, we subjected eight poroid adnexal s
Autor:
Gaurav Goyal, Richa Parikh, Joshua Richman, Jithma P. Abeykoon, Diana Morlote, Ronald S. Go, Smita Bhatia
Publikováno v:
Leukemia Research. 126:107032
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 81, Pp 837-841 (2021)
Current Oncology, Vol 28, Iss 81, Pp 837-841 (2021)
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have b
Publikováno v:
Laboratory Medicine. 52:e53-e56
FLT3 mutations are considered a prognostic and predictive marker. Here we report on a patient with a rare FLT3 germline variant in the context of relapsed acute myeloid leukemia (AML). A female patient aged 57 years presented with AML with mutations
Autor:
Gordon Ruan, Jithma P. Abeykoon, Aldo A. Acosta Medina, Saurabh Zanwar, Aishwarya Ravindran, Karen Rech, Jason R. Young, Jay Ryu, Matthew Koster, W. Oliver Tobin, Mithun V. Shah, N. Nora Bennani, Robert Vassallo, Baylie Brooks, Ginny-Tyler Meadows, Abby McCrory, Diana Morlote, Gaurav Goyal, Ronald Go
Publikováno v:
Blood. 140:3995-3996
Autor:
Saberio Lo Presti MD, Prashanth Kanagarajah MD, Daniela Pirela MD, Diana Morlote MD, Mike Cusnir MD
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 4 (2016)
We report a case of a 38-year-old man presenting with bilateral lower extremity weakness and paresthesias that progressed during a 4-month period to severe polyneuropathy forcing the patient to be bed bound. Throughout his multiple hospitalizations,
Externí odkaz:
https://doaj.org/article/0cfb6f03bba944718c35bae093a42ffb
Publikováno v:
Journal of cutaneous pathologyREFERENCES. 49(2)